Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SYNCHRONIZE-2 (obesity + T2D)

SYNCHRONIZE-2 (obesity + T2D)

Survodutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Survodutide
Population
t2d
Official title
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Sponsor
Boehringer Ingelheim
Phase
3
Registry status
completed · 2023-11 → 2025-12
Participants
755
Duration
76 weeks
Registry
NCT06066528

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
survodutide 3.6 mgt2d76—−10.4 % vs −3.1 %
Δ −7.3 pp
−8.2 % vs −3.9 %
Δ −4.3 pp
−0.9 vs −0.226.4 vs 8.836.0 vs 30.747.6 vs 11.234.4 vs 5.69.2 vs 10.8−3.5 vs −2.7verified
survodutide 6.0 mgt2d76—−13.1 % vs −3.1 %
Δ −10.0 pp
−9.8 % vs −3.9 %
Δ −5.9 pp
−0.8 vs −0.225.9 vs 8.834.7 vs 30.757.4 vs 11.239.0 vs 5.68.4 vs 10.8−3.7 vs −2.7verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (18)
  • survodutide 3.6 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
    the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
  • survodutide 3.6 mg · weight_tp · Table 2
    Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
  • survodutide 3.6 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
  • survodutide 3.6 mg · nausea · Table 3
    Nausea 119 (47.6) 144 (57.4) 28 (11.2)
  • survodutide 3.6 mg · vomiting · Table 3
    Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
  • survodutide 3.6 mg · sae · Table 3
    Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
  • survodutide 3.6 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
  • survodutide 3.6 mg · sbp · Table 2
    Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
  • survodutide 3.6 mg · disc_any · Results, Participants (Fig. S2, Table S3)
    and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
  • survodutide 6.0 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
    the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
  • survodutide 6.0 mg · weight_tp · Table 2
    Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
  • survodutide 6.0 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
  • survodutide 6.0 mg · nausea · Table 3
    Nausea 119 (47.6) 144 (57.4) 28 (11.2)
  • survodutide 6.0 mg · vomiting · Table 3
    Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
  • survodutide 6.0 mg · sae · Table 3
    Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
  • survodutide 6.0 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
  • survodutide 6.0 mg · sbp · Table 2
    Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
  • survodutide 6.0 mg · disc_any · Results, Participants (Fig. S2, Table S3)
    and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.